You are here

Future Perspectives and Further Reading

Chapter 11 - Myelodysplastic Syndromes in the Senior Patient

Future Perspectives

As a result of the development of innovative therapeutic options in MDS including epigenetically active drugs, immune modulating agents, thrombopoietic agents and effective iron chelators, the treatment of elderly MDS patients has become more successful, but also more complex. The results of relevant clinical phase III studies, which might change daily practise, are expected in the near future. To choose the appropriate treatment for an elderly MDS patient, not only chronological age but also aspects of age-adjusted life expectancy, co-morbidities and capacities, as defined by geriatric assessment, have to be integrated, to achieve an individualised therapy-planning and to optimise clinical outcome.

Further Reading

« Previous Page Next Page »